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Abstract
Background:  The Krüppel-like factor (KLF) family consists of transcription factors that can
activate or repress different genes implicated in processes such as differentiation, development, and
cell cycle progression. Moreover, several of these proteins have been implicated in glucose
homeostasis, making them candidate genes for involvement in type 2 diabetes (T2D).
Methods: Variants of nine KLF genes were genotyped in T2D cases and controls and analysed in
a two-stage study. The first case-control set included 365 T2D patients with a strong family history
of T2D and 363 normoglycemic individuals and the second set, 750 T2D patients and 741
normoglycemic individuals, all of French origin. The SNPs of six KLF genes were genotyped by
Taqman® SNP Genotyping Assays. The other three KLF genes (KLF2, -15 and -16) were screened
and the identified frequent variants of these genes were analysed in the case-control studies.
Results: Three of the 28 SNPs showed a trend to be associated with T2D in our first case-control
set (P < 0.10). These SNPs, located in the KLF2, KLF4 and KLF5 gene were then analysed in our
second replication set, but analysis of this set and the combined analysis of the three variants in all
2,219 individuals did not show an association with T2D in this French population. As the KLF2, -15
and -16 variants were representative for the genetic variability in these genes, we conclude they do
not contribute to genetic susceptibility for T2D.
Conclusion: It is unlikely that variants in different members of the KLF gene family play a major
role in T2D in the French population.
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Background
The Krüppel-like factor (KLF) proteins belong to a family
of transcription factors that bind to GC-GT rich sites and
CACC boxes of a large range of gene promoters [1-4].
Binding of these factors is mediated by a highly conserved
DNA-binding motif of C2H2 zinc fingers localised at their
C-terminus [5], which suggests that these proteins could
have a redundant activity. However, accumulated evi-
dence shows that each KLF has its own function and reg-
ulation [6,7]. KLF  transcription factors act as
transcriptional activators or repressors depending on the
specificity of promoters to which they bind and the cellu-
lar context. Moreover, they interact with various co-activa-
tors or co-repressors, regulating via different mechanisms,
the transcription of their target genes [4].
We recently identified both rare and frequent genetic var-
iants in KLF11 co-segregating with early onset familial
diabetes or associated with late-onset T2D [8]. These
results prompted us to assess the putative genetic contri-
bution to T2D risk of additional KLF family members,
especially those presumably involved in energy and glu-
cose homeostasis, through their expression in the pan-
creas, adipose tissue, liver and muscle [9-11]. Indeed,
KLF2, KLF5, and KLF6 have been suggested to be involved
in adipocyte differentiation [12-14]; KLF2 and KLF15 may
contribute to adipogenesis transcriptional regulation via
PPARγ signalling [15,16]. In particular, this implication in
the differentiation process of adipocytes, suggests they
may play an important role in insulin resistance, a status
prone to T2D development.
Thus, the possible implication of the KLF family in glu-
cose homeostasis and adipogenesis makes its members
relevant gene candidates for T2D. Therefore, we assessed
if frequent genetic variants in several members of the KLF
family are implicated in genetic susceptibility to T2D
development in a French population. To assess the puta-
tive contribution of genetic variability of KLFs gene family




Normoglycemic and type 2 diabetic subjects were defined
according to World Health Organization criteria. The
characteristics of the first case-control study, summarized
in table 1, included 365 French T2D unrelated patients
with at least one affected first-degree relative (D1) and
363 non diabetic, unrelated spouses from T2D families
(C1) recruited by the "Centre National de la Recherche
Scientifique"-Institute Pasteur Unit in Lille. The second
sample set (table 1) included 750 T2D patients (D2)
recruited at the Endocrinology-Diabetology Department
of the Corbeil-Essonne Hospital, and 741 control individ-
uals (C2) from the D.E.S.I.R. study (Données Epidemi-
ologiques sur le Syndrome d'Insulino-Resistance [17]).
SNP screening and genotyping
Single nucleotide polymorphisms (SNPs) in putative link-
age disequilibrium blocks of the KLF3, KLF4, KLF5, KLF6,
KLF12, and KLF13 genes were chosen from available Taq-
man® assays (SNP browser 3.0) and genotyped by Taq-
man® SNP Genotyping Assay (Applied Biosystems, Foster
City, CA, U.S.A.). For KLF15 and KLF16 genes, no Taq-
man® probes were available from the SNP Browser 3.0. We
screened the KLF2, KLF15 and KLF16 genes for variants by
direct sequencing of the promoter region (up to 1 kb), the
5' and 3' UTRs, exons and flanking intron sequences of the
genes in DNA samples from 32 unrelated individuals
using the ABI Prism 377 DNA sequencer. The identified
SNPs were genotyped by Light Cycler/Lightyper technol-
ogy (Roche Diagnostic, Basel, Switzerland). SNPs were
genotyped in the first case-control set and those with a
minor allele frequency over 10% (MAF>10%) that
showed a trend to be associated with T2D (P < 0.10) were
further studied in the second case-control set. Duplicate
measurements were included to validate the genotype
scores with 100% of concordance.
Statistical analysis
SNPs of several KLF family members were genotyped in
the first case-control set of 728 individuals. Comparison
of allelic frequencies between cases and controls used a χ2
test with the Pearson P-value under an allelic model
(FINETTI program [18]). The Odds Ratios (ORs) with
95% confidence intervals (CIs) for allelic effects were cal-
culated with the same program. In the first set, D1/C1, the
statistical power, calculated with the PAWE program [19]
to detect an OR of 1.4, was 68% to 84% (α = 0.05, minor
allele frequency (MAF) = 0.15 to 0.20). To increase the
power, we selected SNPs with a significance level of P <
0.10 for further analysis (power = 78% to 90%). The
power to detect an OR of 1.29, previously reported for
KLF11 [8], is 57% to 65% in this set (MAF = 0.15 to 0.20).
We genotyped the selected SNPs in the set D2/C2 of 1,491
individuals. The power of the overall study (D/C) with
2,219 individuals was 99% for an OR = 1.4 (α = 0.05, MAF
= 0.15) and over 84% for the observed ORs (0.75–1.27)
of the selected SNPs in first set D1/C1.
Results
In the first case-control set, we genotyped 28 frequent var-
iants of 9 different members of the KLF gene family with
a minor allele frequency (MAF) above 0.10 (table 2). All
SNPs were in Hardy-Weinberg equilibrium according to
the FINETTI program (data not shown). In table 2, we
present the NCBI reference number (dbSNP ID) and
details for each SNP genotyped, as well as the MAF and the
P-value under an allelic model. From this first study setBMC Medical Genetics 2007, 8:53 http://www.biomedcentral.com/1471-2350/8/53
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(D1/C1), three SNPs showed an association with T2D;
KLF2 rs12459387 (P = 0.09, MAF = 0.12, OR = 0.75 with
95% CI = 0.53–1.05), KLF4 rs10759240 (P = 0.08, MAF =
0.52, OR = 0.83 with 95% CI = 0.67–1.02) and KLF5
rs11841945 (P = 0.04, MAF = 0.40, OR = 1.27 with 95%
CI = 1.02–1.59).
In the second case-control set, we genotyped KLF2
rs12459387,  KLF4  rs10759240 and KLF5  rs11841945,
but the observed difference in MAF between cases and
controls in D1/C1 was not confirmed (Table 2). In fact,
the trend for allelic association with T2D observed in the
first set was not replicated for these SNPs in the second set
(D2/C2), nor were they significant after the combined
analysis of both groups (D/C). As D2 had a higher mean
body mass index (BMI) compared to D1, we also analyzed
the data of individuals with BMI < 27 kg/m2 but still no
significant difference was observed. In addition, we did
not observe associations between these three SNPs and
quantitative traits such as fasting insulin, fasting glucose,
OGTT.
Since our study is probably limited by the fact that it does
not cover all the genetic variability of the KLF genes, we
analysed additional SNPs included in our recently pub-
lished genome wide association study [20]. The SNPs
located in regions spanning the KLF genes, and analyzed
in this genome wide association study (148) showed no
significant association with T2D in this French population
(data not shown).
Discussion
We have analysed SNPs within nine KLF genes and we
were not able to show a genetic T2D association in our
population. A similar study in a Japanese population also
showed no evidence for an association with other variants
of the same KLF genes analysed in our study (KLF2, -3, -5,
-12, -13 and KLF16 [21]). However, it is worth noting that
some KLF genes are not covered extensively with HapMap
genotyped SNPs. In fact, this was the case for KLF15 and
KLF16 gene regions, where at the start of this study no
Taqman® assays were available. Therefore, we decided to
screen these genes for common SNPs. Since we analysed
in our study all frequent SNPs without any positive
results, we conclude that the KLF15 and KLF16 genes are
not likely to be associated with T2D in a French popula-
tion.
A limitation of our study is the two-staged design, through
which we may have missed a weak but true association
with T2D. However, the use of T2D patients with affected
first degree relatives and controls sharing the same envi-
ronment as the cases in set 1, probably increased our
power to detect an association with T2D. A second limita-
tion of this study is the fact that it does not cover all the
genetic variability of the KLF genes. However, our subse-
quent genome wide association analysis with 1,363 indi-
viduals also did not show significant T2D associations for
variants of these genes, making it unlikely the nine KLFs
play a major role in genetic T2D susceptibility.
We hypothesised that KLF genes could be associated with
genetic susceptibility for T2D, based on their role in adi-
pogenesis. In particularly, KLF2 is implicated in the regu-
lation of PPARγ [15], which is a target gene implicated in
the genetic susceptibility for T2D. Therefore, we studied
this gene more extensively and genotyped 9 SNPs. Also for
KLF2 variants, we did not observe an association with T2D
in this French population. In addition, a previous study of
KLF2 variants and body weight control in another French
population did not observe an association with adipose
tissue-related traits [22]. From these results, it seems
unlikely that the genetic variability of the KLF2 gene plays
a mayor role in susceptibility to T2D or obesity.
Conclusion
In our study of variants from nine different members of
the KLF gene family, we observed no association with T2D
in our large French population. Moreover, the genotyped
SNPs covered the overall genetic variability of the KLF2, -
15 and -16 genes so we may conclude that these genes do
not contribute to the genetic susceptibility of T2D.
Table 1: General characteristics of the French populations studied
Case-control Set 1 Case-Control Set 2
D, type 2 diabetic patients; 
C, control individuals
(D1) (C1) (D2) (C2)
Numbers studied 365 363 750 741
Sex (men/women) 196/169 136/227 455/295 294/447
Age at examination (years, 
mean ± SD)
- 59 ± 13 - 53 ± 6
Age at diagnosis of diabetes 
(years, mean ± SD)
45 ± 11 - 48 ± 10 -
BMI (kg/m2, mean ± SD) 26.8 ± 3.8 25.4 ± 4.7 33.0 ± 6.4 23.0 ± 1.8BMC Medical Genetics 2007, 8:53 http://www.biomedcentral.com/1471-2350/8/53
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Table 2: Genotypic distribution of KLF SNPs in type 2 diabetic and non-diabetic individuals





KLF2, Chr. 19q13 0.31 (167, 142, 34) 0.69
Prom -789 C/T 0.32 (148, 143, 30)
rs10424657 G/A 0.30 (175, 146, 34) 0.61
0.31 (162, 155, 32)
rs12459387 C/T 0.09 (292, 58, 4) 0.09 0.10 (464, 106, 6) 0.87 0.10 (756, 164, 10) 0.40
0.12 (260, 78, 2) 0.10 (543, 123, 6) 0.11 (803, 201, 8)
rs7248864 C/T 0.09 (295, 56, 5) 0.13
0.12 (270, 78, 2)
rs3745318 C/T 0.21 (211, 109, 16) 0.67
0.20 (214, 114, 11)
rs12462380 A/G 0.41 (119, 178, 56) 0.24
0.44 (102, 170, 63)
rs7258799 A/T 0.13 (277, 81, 6) 0.15
0.16 (219, 74, 10)
rs15336 C/A 0.19 (235, 111, 12) 0.21
0.16 (235, 94, 8)
rs11086029 A/T 0.22 (209, 121, 14) 0.63
0.21 (217, 117, 13)
KLF3, Chr. 4q14 0.44 (110, 180, 70) 0.89
rs2045767 G/T 0.45 (105, 182, 68)
rs9522 C/T 0.45 (110, 171, 75) 0.62
0.46 (97, 178, 72)
KLF4, Chr. 9q31 0.47 (97, 174, 79) 0.08 0.49 (144, 297, 133) 0.68 0.48 (241, 471, 212) 0.08
rs10759240 C/A 0.52 (80, 168, 95) 0.51 (176, 361, 187) 0.51 (256, 529, 282)
KLF5, Chr. 13q21 0.16 (248, 97, 6) 0.67
rs12428414 C/T 0.16 (237, 88, 11)
rs4885065 A/G 0.17 (245, 94, 11) 0.83
0.16 (247, 98, 8)
rs9564944 A/G 0.12 (263, 69, 5) 0.90
0.12 (269, 62, 8)
rs11841945 C/G 0.46 (94, 173, 65) 0.04 0.42 (200, 271, 110) 0.20 0.43 (294, 444, 175) 0.91
0.40 (110, 145, 48) 0.45 (227, 349, 151) 0.43 (337, 494, 199)
KLF6, Chr. 10p15 0.11 (290, 68, 5) 0.63
rs7005 C/T 0.12 (281, 66, 8)
KLF12, Chr. 13q21 0.36 (148, 164, 47) 0.36
rs1927010 A/T 0.32 (154, 162, 38)
rs4885151 G/T 0.31 (165, 166, 31) 0.80
0.32 (169, 144, 42)
rs7993625 C/T 0.24 (205, 128, 21) 0.60
0.23 (199, 133, 12)
rs6650443 A/G 0.19 (245, 99, 19) 0.66
0.20 (224, 107, 15)
rs9600167 C/G 0.35 (154, 158, 46) 0.49
0.23 (160, 141, 44)
KLF13, Chr. 15q12 0.44 (120, 169, 74) 0.71
rs11855557 A/G 0.45 (102, 189, 64)
rs12592176 G/A 0.50 (84, 186, 83) 0.49
0.48 (98, 172, 84)
rs4779516 T/C 0.44 (115, 175, 70) 0.36
0.46 (96, 187, 69)
KLF15, Chr. 3q13 0.12 (268, 74, 4) 0.35
3'UTR+244del(CACGAAGG) 0.10 (285, 58, 7)
KLF16, Chr. 19q13 0.47 (100, 162, 79) 0.11
rs11670146 A/G 0.47 (101, 144, 56)
rs3746045 T/C 0.24 (208, 120, 24) 0.23
0.21 (214, 119, 14)
D, type 2 diabetic patients; C, non-diabetic individuals; MAF, minor allele frequency; (number of subjects with wild type homozygote; heterozygote; 
mutant homozygote alleles); P-value for differences between allele frequencies under an allelic model.Publish with BioMed Central    and   every 
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